KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EBT (2016 - 2026)

Bio-Rad Laboratories has reported EBT over the past 18 years, most recently at -$689.8 million for Q1 2026.

  • Quarterly EBT fell 927.1% to -$689.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $222.3 million through Mar 2026, up 108.08% year-over-year, with the annual reading at $995.5 million for FY2025, 142.5% up from the prior year.
  • EBT was -$689.8 million for Q1 2026 at Bio-Rad Laboratories, down from $929.2 million in the prior quarter.
  • Over five years, EBT peaked at $1.1 billion in Q4 2022 and troughed at -$4.4 billion in Q1 2022.
  • The 5-year median for EBT is $83.4 million (2025), against an average of -$446.5 million.
  • Year-over-year, EBT surged 528.45% in 2024 and then tumbled 927.1% in 2026.
  • A 5-year view of EBT shows it stood at $1.1 billion in 2022, then tumbled by 60.75% to $428.4 million in 2023, then plummeted by 312.16% to -$908.9 million in 2024, then surged by 202.23% to $929.2 million in 2025, then plummeted by 174.24% to -$689.8 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's EBT are -$689.8 million (Q1 2026), $929.2 million (Q4 2025), and -$431.1 million (Q3 2025).